# OnCo record paper-parsons-mrd-early-breast-cancer-clin-cancer-res-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-parsons-mrd-early-breast-cancer-clin-cancer-res-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-parsons-mrd-early-breast-cancer-clin-cancer-res-2020" ;
  schema:name "Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer"@en ;
  schema:description "A breast cancer blood test that tracked hundreds of each patient's tumour mutations found leftover disease that predicted relapse, but most patients' tumours had far fewer mutations to track, and that set how sensitive the test could be."@en ;
  schema:url <https://onco.cc/key-papers/paper-parsons-mrd-early-breast-cancer-clin-cancer-res-2020/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/1078-0432.CCR-19-3005>, <https://pubmed.ncbi.nlm.nih.gov/32170028/> ;
  schema:sameAs <https://doi.org/10.1158/1078-0432.CCR-19-3005> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Parsons HA, Rhoades J, Reed SC, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-subclone-attribution-residual-disease/> ;
  onco:journals <https://onco.cc/journals/clinical-cancer-research/> .